.png)
John Riley, Ph.D., is our Director of N.A. API Sales Technical Support, drawing on his deep expertise to guide our teams and enhance the execution of our API projects.
.png)
Accelerating the design-make-test-analyze (DMTA) cycle that underpins all drug discovery programs offers a significant competitive advantage, helping drug developers reach the clinic and market before their rivals while also minimizing costs.
.png)
Drug development is increasingly complex, requiring rapid, informed decision-making throughout the product life cycle and across manufacturing sites. Access to a broad, deep scientific pool of pharmaceutical development expertise is especially critical when developing novel therapies, formulating for targeted patient groups, and dealing with technical challenges that can arise without warning.
Starting from a previously validated molecule is one of the fastest ways to reach the clinic, but the IP economics are unforgiving. Molecules that closely track prior art offer weak IP protection, and method-of-use claims often fail to defend a market position.
.jpg)
-1-1.png)
-3.png)
-2-1.png)
-2.png)
.png)
